Plasma Levels of Soluble Urokinase-Type Plasminogen Activator Receptor Associate with the Clinical Severity of Acute Puumala Hantavirus Infection

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Outinen, Tuula K ^a,b   Tervo, Laura ^a   Mäkelä, Satu ^a,b   Huttunen, Reetta ^a,b   Mäenpää, Niina ^b,c   Huhtala, Heini ^b   Vaheri, Antti ^d   Mustonen, Jukka ^a,b   Aittoniemi, Janne ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c FIMLAB LABORATORIES   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; DNA; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; PENTRAXIN 3; UROKINASE RECEPTOR;

ACUTE PUUMALA HANTAVIRUS INFECTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HANTAVIRUS; HANTAVIRUS INFECTION; HEMATOCRIT; HUMAN; HUMAN CELL; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PUUMALA VIRUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEIGHT CHANGE;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PUUMALA VIRUS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84882730282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071335     Document Type: Article

References (47)

1. Vapalahti O, Mustonen J, Lundkvist Å, Henttonen H, Plyusnin A, et al. (2003) Hantavirus infections in Europe. Lancet Infect Dis 3: 653-661.
2. Vaheri A, Henttonen H, Voutilainen L, Mustonen J, Sironen T, et al. (2013) Hantavirus infections in Europe and their impact on public health. Rev Med Virol 23: 35-49.
3. Heyman P, Vaheri A, (2008) Situation of hantavirus infections and haemorrhagic fever with renal syndrome in European countries as of December 2006. Euro Surveill 13.
4. Makary P, Kanerva M, Ollgren J, Virtanen MJ, Vapalahti O, et al. (2010) Disease burden of Puumala virus infections, 1995-2008. Epidemiol Infect 138: 1484-1492.
5. Lähdevirta J, (1971) Nephropathia epidemica in Finland. A clinical histological and epidemiological study. Ann Clin Res 3: 1-54.
6. Mustonen J, Brummer-Korvenkontio M, Hedman K, Pasternack A, Pietilä K, et al. (1994) Nephropathia epidemica in Finland: a retrospective study of 126 cases. Scand J Infect Dis 26: 7-13.
7. Settergren B, Juto P, Trollfors B, Wadell G, Norrby SR, (1989) Clinical characteristics of nephropathia epidemica in Sweden: prospective study of 74 cases. Rev Infect Dis 11: 921-927.
8. Braun N, Haap M, Overkamp D, Kimmel M, Alscher MD, et al. (2010) Characterization and outcome following Puumala virus infection: a retrospective analysis of 75 cases. Nephrol Dial Transplant 25: 2997-3003.
9. Kanerva M, Paakkala A, Mustonen J, Paakkala T, Lahtela J, et al. (1996) Pulmonary involvement in nephropathia epidemica: radiological findings and their clinical correlations. Clin Nephrol 46: 369-378.
10. Paakkala A, Mustonen J, (2007) Radiological findings and their clinical correlations in nephropathia epidemica. Acta Radiol 48: 345-350.
11. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, et al. (1995) Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 146: 552-579.
12. Cosgriff TM, (1991) Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome. Rev Infect Dis 13: 97-107.
13. Kanerva M, Mustonen J, Vaheri A, (1998) Pathogenesis of Puumala and other hantavirus infections. Rev Med Virol 8: 67-86.
14. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER, (1998) beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 95: 7074-7079.
15. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER, (1999) Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol 73: 3951-3959.
16. Outinen TK, Kuparinen T, Jylhävä J, Leppänen S, Mustonen J, et al. (2012) Plasma cell-free DNA levels are elevated in acute Puumala hantavirus infection. PLoS One 7: e31455.
17. Outinen TK, Mäkelä S, Huhtala H, Hurme M, Meri S, et al. (2012) High pentraxin-3 plasma levels associate with thrombocytopenia in acute Puumala hantavirus-induced nephropathia epidemica. Eur J Clin Microbiol Infect Dis 31: 957-963.
18. Outinen TK, Mäkelä SM, Ala-Houhala IO, Huhtala HS, Hurme M, et al. (2011) High activity of indoleamine 2,3-dioxygenase is associated with renal insufficiency in Puumala hantavirus induced nephropathia epidemica. J Med Virol 83: 731-737.
19. Outinen TK, Mäkelä SM, Ala-Houhala IO, Huhtala HS, Hurme M, et al. (2010) The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect Dis 10: 132.
20. Libraty DH, Mäkelä S, Vlk J, Hurme M, Vaheri A, et al. (2012) The Degree of Leukocytosis and Urine GATA-3 mRNA Levels Are Risk Factors for Severe Acute Kidney Injury in Puumala Virus Nephropathia Epidemica. PLoS One 7: e35402.
21. Ossowski L, Aguirre-Ghiso JA, (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12: 613-620.
22. Thuno M, Macho B, Eugen-Olsen J, (2009) suPAR: the molecular crystal ball. Dis Markers 27: 157-172.
23. Mustjoki S, Sidenius N, Vaheri A, (2000) Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. FEBS Lett 486: 237-242.
24. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, et al. (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6: 686-692.
25. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, et al. (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270: 32-40.
26. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, et al. (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15: R63.
27. Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A, (2011) Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 30: 1417-1424.
28. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, et al. (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96: 4091-4095.
29. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, et al. (2005) Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 191: 1331-1341.
30. Uusitalo-Seppälä R, Huttunen R, Tarkka M, Aittoniemi J, Koskinen P, et al. (2012) Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 272: 247-256.
31. Vapalahti O, Lundkvist Å, Kallio-Kokko H, Paukku K, Julkunen I, et al. (1996) Antigenic properties and diagnostic potential of Puumala virus nucleocapsid protein expressed in insect cells. J Clin Microbiol 34: 119-125.
32. Laine O, Joutsi-Korhonen L, Mäkelä S, Mikkelsson J, Pessi T, et al. (2012) Polymorphisms of PAI-1 and platelet GP Ia may associate with impairment of renal function and thrombocytopenia in Puumala hantavirus infection. Thromb Res 129: 611-615.
33. Laine O, Mäkelä S, Mustonen J, Helminen M, Vaheri A, et al. (2011) Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia. Blood Coagul Fibrinolysis 22: 468-472.
34. Laine O, Mäkelä S, Mustonen J, Huhtala H, Szanto T, et al. (2010) Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. Thromb Res 126: 154-158.
35. Sane J, Laine O, Mäkelä S, Paakkala A, Jarva H, et al. (2012) Complement activation in Puumala hantavirus infection correlates with disease severity. Ann Med 44: 468-475.
36. Mäkelä S, Mustonen J, Ala-Houhala I, Hurme M, Koivisto AM, et al. (2004) Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. Am J Kidney Dis 43: 809-816.
37. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D, (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364: 82-90.
38. Laich A, Neurauter G, Widner B, Fuchs D, (2002) More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 48: 579-581.
39. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, et al. (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268: 296-308.
40. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, et al. (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35: 337-342.
41. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, et al. (2005) High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 39: 23-31.
42. Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, et al. (2011) The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol 50: 209-211.
43. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J, (2004) Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 36: 14-19.
44. Garcia-Monco JC, Coleman JL, Benach JL, (2002) Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 129: 216-223.
45. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE, (2012) Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 46: 334-338.
46. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, et al. (2011) Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis 30: 761-766.
47. Mackow ER, Gavrilovskaya IN, (2009) Hantavirus regulation of endothelial cell functions. Thromb Haemost 102: 1030-1041.